IG Stock Recent News IGI Laboratories (IG) 9.45 11/09/2014 1

New Post Public Reply Private Reply Replies (0) Message Board

Nov 9, 2014 at 11:55 AM

IGI Laboratories (IG) 9.45 $IG

Flamel Technologies (FLML) Crumbles: Stock Falls by 7.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 03, 7:38AM CST
Flamel Technologies (FLML) fell over 7% in the last trading session amid huge volumes, continuing its recent trend, as the stock is now down nearly 15% in the past one-month time frame.
FLML: 11.80 (-0.23), AUXL: 32.75 (-0.52), IG: 9.45 (-0.25), BIOD: 1.54 (+0.01)

Strength Seen in Cempra (CEMP): Stock Rises 10.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Oct 31, 8:25AM CDT
Cempra (CEMP) was a big mover last session, with shares rising over 10% on the day.
LCI: 50.17 (-0.82), ADHD: 3.75 (-0.12), CEMP: 13.76 (-0.24), IG: 9.45 (-0.25)

Synergy Pharmaceuticals, Inc. (SGYP) Surges: Stock Rises 10% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Oct 30, 8:11AM CDT
Synergy Pharmaceuticals, Inc. (SGYP) was a big mover last session, as the company saw its shares rise 10% on the day.
SGYP: 3.16 (+0.18), ADHD: 3.75 (-0.12), IG: 9.45 (-0.25), BIOD: 1.54 (+0.01)

Receptos (RCPT) Worth Watching: Stock Moves Up 41.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 8:39AM CDT
Receptos, Inc. (RCPT) was a big mover last session, as its shares rose over 41% on the day.
LCI: 50.17 (-0.82), PTLA: 27.39 (-0.33), RCPT: 109.24 (-1.28), IG: 9.45 (-0.25)

Strength Seen in Zafgen (ZFGN): Stock Adds 7.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:51AM CDT
Zafgen, Inc. (ZFGN) was a big mover last session, as its shares rose over 7% on the day.
LCI: 50.17 (-0.82), ZFGN: 19.18 (-0.13), PTLA: 27.39 (-0.33), IG: 9.45 (-0.25)

Should IGI, Laboratories (IG) Be On Your Radar Now? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Oct 29, 7:47AM CDT
IGI, Laboratories has been overlooked by investors but it has actually seen estimates rise over the past month.
IG: 9.45 (-0.25)

IGI Laboratories Inc (IG) Upgraded From Hold to Buy
at The Street - Tue Oct 28, 8:38AM CDT
IGI Laboratories Inc (IG) has been upgraded by TheStreet Ratings from Hold to Buy with a ratings score of B.
IG: 9.45 (-0.25)

NanoViricides (NNVC) Jumps: Stock Adds 9.4% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 8:04AM CDT
NanoViricides, Inc. (NNVC) was a big mover last session, as the company saw its shares rise over 9% on the day.
ADHD: 3.75 (-0.12), NNVC: 3.57 (-0.12), IG: 9.45 (-0.25), BIOD: 1.54 (+0.01)

Regulus Therapeutics (RGLS) Soars: Stock Rises 6.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Oct 28, 7:51AM CDT
Regulus Therapeutics Inc. (RGLS) was a big mover last session, as its shares rose almost 7% on the day.
LCI: 50.17 (-0.82), PTLA: 27.39 (-0.33), RGLS: 22.08 (+2.42), IG: 9.45 (-0.25)

La Jolla Pharmaceutical Co. (LJPC) Jumps: Stock Rises 10.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Oct 27, 8:32AM CDT
La Jolla Pharmaceutical Co. (LJPC) was a big mover last session, as the company saw its shares rise more than 10% on the day.
LJPC: 12.28 (+1.14), CEMP: 13.76 (-0.24), IG: 9.45 (-0.25), BIOD: 1.54 (+0.01)

IGI Laboratories Announces Third Quarter 2014 Results
PR Newswire - Thu Oct 23, 3:05PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, announced its financial results for the third quarter ended September 30, 2014.
IG: 9.45 (-0.25)

IGI Laboratories To Hold Conference Call For 3rd Quarter 2014 Results
PR Newswire - Mon Oct 20, 7:00AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:15 pm ET on Thursday, October 23, 2014 to discuss the 3rd quarter 2014 results.
IG: 9.45 (-0.25)

IGI Laboratories, Inc. Appoints Steven Koehler To Board Of Directors
PR Newswire - Thu Oct 09, 3:05PM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey-based specialty generic pharmaceutical company, today announced that it has appointed Steven Koehler to its Board of Directors. Mr. Koehler will serve as the new Chairman of the Company's Audit Committee.
IG: 9.45 (-0.25)

IGI Laboratories, Inc. Acquires Two Products From Valeant Pharmaceuticals
PR Newswire - Wed Oct 01, 7:00AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has acquired two previously marketed ophthalmic drug products, in addition to the right to acquire three additional previously marketed injectable drug products from affiliates of Valeant Pharmaceuticals International, Inc. after the completion of the due diligence process. All of these products have been approved by the FDA as abbreviated new drug applications (ANDAs) or new drug applications (NDAs). According to IMS Health, the current addressable market in the United States for the therapeutic areas that all of these products were previously indicated for is estimated at $38 million as of August 2014.
IG: 9.45 (-0.25), VRX.TO: 142.84 (-4.34)

Can the Uptrend Continue for IGI, Laboratories (IG)? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 9:08AM CDT
Can the Uptrend Continue for IGI, Laboratories (IG)?
IG: 9.45 (-0.25)

IGI, Laboratories (IG) Jumps: Stock Up 18.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Sep 26, 7:51AM CDT
IGI, Laboratories, Inc. (IG) was a big mover last session, as the company shares rose over 18% on the day.
LCI: 50.17 (-0.82), ENDP: 68.96 (-1.23), IG: 9.45 (-0.25), HPTX: 21.82 (-1.83)

Market Maker Surveillance Report. IG, CNET, STV, AIXG, MDBX, RGDO, Winning Stocks With Lowest Price Friction For Thursday, September 25th 2014
M2 - Fri Sep 26, 3:29AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Thursday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Thursday there were 4456 companies with "abnormal" market making, 1102 companies with positive Friction Factors and 4256 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Thursday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. IGI Laboratories Inc (NYSE:IG), Chinanet Online Holdings Inc (NASDAQ:CNET), China Digital Tv Holding Co Ltd (NYSE:STV), Aixtron SE (NASDAQ:AIXG), (OTC:MDBX), (NASDAQ:RGDO). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
AIXG: 11.96 (+0.10), STV: 3.94 (-0.03), CNET: 2.11 (+0.01), IG: 9.45 (-0.25), RGDO: 0.93 (-0.02)

Why IGI Laboratories (IG) Stock Hit a One-Year High Today
at The Street - Thu Sep 25, 1:56PM CDT
Shares of IGI Laboratories (IG) soared to a 52-week high of $9.01 on Thursday after the pharmaceutical company announced it had acquired regulatory rights to 18 AstraZeneca AZN drugs.
AZN: 72.88 (+0.03), IG: 9.45 (-0.25)

IGI Laboratories, Inc. Acquires Eighteen Former Products From AstraZeneca
PR Newswire - Thu Sep 25, 7:30AM CDT
IGI Laboratories, Inc. (NYSE MKT: IG), a New Jersey based specialty generic pharmaceutical company, today announced it has acquired the regulatory rights and related documents and records for 18 drug products from AstraZeneca, 17 of which were marketed. The acquisition includes the regulatory rights and documents for 17 injectable products and 1 suppository product. All of these products had been previously approved by the US FDA as abbreviated new drug applications (ANDAs) or new drug applications (NDAs) prior to their discontinuation or withdrawal from the market. According to IMS Health, the current addressable market in the United States for the therapeutic areas that these products were previously indicated for is estimated at $200 million as of May 2014.
IG: 9.45 (-0.25)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Novo's Research Unlocks New Insights into Food Noise

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

BETR's Slide: Investors Face Big Losses, Leadership Shift

BETR Investors Left in the Lurch It's a real trainwreck, folks. Better Home & Finance Holding Company, trading under NASDAQ:BETR, is in the spotlight for all the wrong reasons. The company expanded the class period for its investor lawsuit to include even more dates between March and August 2026, reflecting a torturous ride for shareholders. Their stock cratered by a...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

AppLovin Legal Woes: A Deep Dive into Investor Claims

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Fluence Energy Faces Leadership Departures Amid Legal Woes

Fluence Energy's Rocky Road Continues It's chaos once again in the halls of Fluence Energy (NASDAQ:FLNC). The ship seems to drift further from solid ground as their CEO and CFO candidly decided to jump ship, shaking investor confidence even more vigorously. The market's reaction was swift and brutal: a nasty 9% share drop, leaving investors with more than just a headache....

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Layne's Chicken Fingers Expands with Brownsville Opening

Fried Delights Rise in Brownsville Never thought I'd see the day when chicken fingers felt like the main character in an epic expansion saga, but here we are. Ricki Oberoi, a veteran in the fast-food game, is pushing onward with Layne's Chicken Fingers in Brownsville, Texas. I tell you, some folks are as keen on expanding their palates as they are their portfolios....

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...